{"id":"nebivolol-diltiazem","safety":{"commonSideEffects":[{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nebivolol is a selective beta-1 adrenergic receptor antagonist with vasodilatory properties that reduces heart rate and contractility. Diltiazem is a non-dihydropyridine calcium channel blocker that slows atrioventricular node conduction and causes vasodilation. The combination provides additive cardiovascular effects for blood pressure control and heart rate reduction.","oneSentence":"Nebivolol and diltiazem work together as a beta-blocker and calcium channel blocker to reduce heart rate, blood pressure, and cardiac workload.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:34:57.896Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Angina pectoris"},{"name":"Atrial fibrillation"}]},"trialDetails":[{"nctId":"NCT04513509","phase":"NA","title":"Rate Control in Patients With Atrial Fibrillation","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2020-10-21","conditions":"Atrial Fibrillation, Rate Control, Cardiopulmonary Exercise Test","enrollment":13},{"nctId":"NCT04130438","phase":"PHASE2","title":"Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging","status":"TERMINATED","sponsor":"Stanford University","startDate":"2020-10-15","conditions":"Myocardial Bridging","enrollment":5},{"nctId":"NCT02391337","phase":"PHASE4","title":"Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)","status":"COMPLETED","sponsor":"University of Birmingham","startDate":"2016-12-20","conditions":"Permanent Atrial Fibrillation","enrollment":161},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT03930433","phase":"PHASE4","title":"The Effect of Nebivolol in Hypertensive Patients With Coronary Arterial Spasm","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2018-01-01","conditions":"Coronary Vasospasm","enrollment":51},{"nctId":"NCT00223717","phase":"PHASE1","title":"Treatment of Supine Hypertension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2001-01","conditions":"Hypertension","enrollment":152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Nebivolol+Diltiazem","genericName":"Nebivolol+Diltiazem","companyName":"Korea University Anam Hospital","companyId":"korea-university-anam-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nebivolol and diltiazem work together as a beta-blocker and calcium channel blocker to reduce heart rate, blood pressure, and cardiac workload. Used for Hypertension, Angina pectoris, Atrial fibrillation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}